구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF 244 trials·t½ Extended intravitreal half-life vs Fab fragments (~4–6 days vitreal, sustained biologic effect q4–8w) | faricimab (Vabysmo, RG7716, faricimab-svoa) Roche / Genentech·Ang-2 / VEGF-A 53 trials·t½ Ocular ~7.5 days; minimal systemic exposure by design | voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl) Spark Therapeutics / Roche·RPE65 (AAV2) 7 trials | |
|---|---|---|---|---|
Overview Program | Eylea (aflibercept) | Lucentis (ranibizumab) | Vabysmo (faricimab) | Luxturna (voretigene neparvovec) |
Overview Company | Regeneron / Bayer | Roche / Genentech | Roche / Genentech | Spark Therapeutics / Roche |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | CGT |
Overview Target | VEGF-A / VEGF-B / PIGF | VEGF-A | Ang-2 / VEGF-A | RPE65 (AAV2) |
Overview Indication | Wet AMD, DME, RVO, diabetic retinopathy | Wet AMD, DME, RVO, myopic CNV | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion | Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | unique records | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. | Surgical subretinal delivery; landmark ophthalmology gene therapy |
Positioning Known limitation | Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients. | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. | bypasses defective phototransduction pathways, showing promise for patients regardless of their genetic profile |
Positioning Development positioning | — | — | Primary challenger to Eylea/Eylea HD on injection interval. | Only approved RPE65 gene therapy |
Technology Vector | — | — | — | AAV2 |
MoA Mechanism | Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina. | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. | Voretigene neparvovec uses AAV2 to deliver functional RPE65 to retinal pigment epithelium, restoring the visual cycle and improving light sensitivity in RPE65-mutant IRD. |
MoA Biomarker | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | biomarker of treatment response, supporting further validation in larger independent cohorts | OCT central subfield thickness, BCVA, presence of intraretinal fluid. | MLMT, FST, BCVA. |
PK/PD Half-life | Extended intravitreal half-life vs Fab fragments (~4–6 days vitreal, sustained biologic effect q4–8w) | 9 h | Ocular ~7.5 days; minimal systemic exposure by design | — |
PK/PD Species | Mouse, CST reduction, BCVA gain | Mouse | Human, primate, CST reduction, fluid-free intervals, BCVA change | NHP, Despite these findings, and no systemic toxicity was identified. |
PK/PD Animal (cat.) | Mouse | Mouse | Human | NHP |
PK/PD Experiment | Pharmacokinetic | pharmacokinetic | pharmacokinetic | biodistribution |
Toxicology Species | Cynomolgus monkey, Mouse | Mouse | Rat | NHP, Dog, Despite these findings, and no systemic toxicity was identified. |
Toxicology Animal (cat.) | NHP | — | — | NHP, Dog |
Toxicology Major finding | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids |
Toxicology CRS | N/A | N/A | N/A | — |
Clinical Safety signal | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids |
Clinical Selected reported efficacy | 58% | 50% | 16.9% | — |
Clinical Result source | ClinicalTrials.gov NCT05275205 | ClinicalTrials.gov NCT00473642 | ClinicalTrials.gov NCT04740905 | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | 4 recruiting · 3 completed |
Clinical Trial ref | NCT05275205 | NCT00473642 | NCT04740905 | — |
Preclinical Animal (cat.) | Mouse | — | Rat | NHP |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF 244 trials·t½ Extended intravitreal half-life vs Fab fragments (~4–6 days vitreal, sustained biologic effect q4–8w) | faricimab (Vabysmo, RG7716, faricimab-svoa) Roche / Genentech·Ang-2 / VEGF-A 53 trials·t½ Ocular ~7.5 days; minimal systemic exposure by design | voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl) Spark Therapeutics / Roche·RPE65 (AAV2) 7 trials | |
|---|---|---|---|---|
Overview Program | Eylea (aflibercept) | Lucentis (ranibizumab) | Vabysmo (faricimab) | Luxturna (voretigene neparvovec) |
Overview Company | Regeneron / Bayer | Roche / Genentech | Roche / Genentech | Spark Therapeutics / Roche |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | CGT |
Overview Target | VEGF-A / VEGF-B / PIGF | VEGF-A | Ang-2 / VEGF-A | RPE65 (AAV2) |
Overview Indication | Wet AMD, DME, RVO, diabetic retinopathy | Wet AMD, DME, RVO, myopic CNV | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion | Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | unique records | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. | Surgical subretinal delivery; landmark ophthalmology gene therapy |
Positioning Known limitation | Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients. | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. | bypasses defective phototransduction pathways, showing promise for patients regardless of their genetic profile |
Positioning Development positioning | — | — | Primary challenger to Eylea/Eylea HD on injection interval. | Only approved RPE65 gene therapy |
Technology Vector | — | — | — | AAV2 |
MoA Mechanism | Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina. | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. | Voretigene neparvovec uses AAV2 to deliver functional RPE65 to retinal pigment epithelium, restoring the visual cycle and improving light sensitivity in RPE65-mutant IRD. |
MoA Biomarker | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | biomarker of treatment response, supporting further validation in larger independent cohorts | OCT central subfield thickness, BCVA, presence of intraretinal fluid. | MLMT, FST, BCVA. |
PK/PD Half-life | Extended intravitreal half-life vs Fab fragments (~4–6 days vitreal, sustained biologic effect q4–8w) | 9 h | Ocular ~7.5 days; minimal systemic exposure by design | — |
PK/PD Species | Mouse, CST reduction, BCVA gain | Mouse | Human, primate, CST reduction, fluid-free intervals, BCVA change | NHP, Despite these findings, and no systemic toxicity was identified. |
PK/PD Animal (cat.) | Mouse | Mouse | Human | NHP |
PK/PD Experiment | Pharmacokinetic | pharmacokinetic | pharmacokinetic | biodistribution |
Toxicology Species | Cynomolgus monkey, Mouse | Mouse | Rat | NHP, Dog, Despite these findings, and no systemic toxicity was identified. |
Toxicology Animal (cat.) | NHP | — | — | NHP, Dog |
Toxicology Major finding | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids |
Toxicology CRS | N/A | N/A | N/A | — |
Clinical Safety signal | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids |
Clinical Selected reported efficacy | 58% | 50% | 16.9% | — |
Clinical Result source | ClinicalTrials.gov NCT05275205 | ClinicalTrials.gov NCT00473642 | ClinicalTrials.gov NCT04740905 | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | 4 recruiting · 3 completed |
Clinical Trial ref | NCT05275205 | NCT00473642 | NCT04740905 | — |
Preclinical Animal (cat.) | Mouse | — | Rat | NHP |
추천 비교
추천 비교